Henry Danahay

Dr Henry Danahay gained a BPharm and PhD from the Welsh School of Pharmacy before joining the Novartis Respiratory Diseases Group. Whilst with Novartis, he worked as an in vitro/in vivo pharmacologist with a specialisation in airway epithelial cell based drug targets. During this time he played a central role in establishing the CF discovery portfolio and was most recently Director and Head of the Lung Repair & Regeneration Group in the Respiratory Disease Area. He has lead a number of drug discovery programs from target identification through to early clinical studies as well as authoring >40 peer reviewed papers and patents. As a co-founder of Enterprise Therapeutics, Dr Danahay is Head of Biology and is an honorary Senior Research Fellow at the University of Sussex.

Henry Danahay is the Head of Biology at Enterprise Therapeutics, based in Europe. With a background in Health Care, Henry Danahay has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.